March 29, 2017
Faron Pharmaceuticals reports €9.2M loss for 2016
Faron Pharmaceuticals, the clinical stage biopharmaceutical company, has reported full year audited results for the year ended 31 December 2016.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
March 29, 2017
Allergy Therapeutics reports €7.9M for second half od 2016
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
March 29, 2017
Alliance Pharma’s profit up to €20M
Alliance Pharma, the specialty pharmaceutical company, has announced results for the year ended 31 December 2016.
March 29, 2017
Stada’s 2016 profit down 22%
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
March 29, 2017
Omega markets malaria tests
A medical diagnostics company focused on allergy, food intolerance and infectious disease, Omega, has CE-Marked its Visitect range of Malaria tests.
March 29, 2017
AstraZeneca’s and MedImmune’s NMOSD drug gets EMA’s orphan designation
European Medicines Agency (EMA) has granted orphan designation to AstraZeneca’s and MedImmune’s inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
March 29, 2017
Guerbet reports €10M less profit for 2016
Guerbet, a global specialist in contrast agents and solutions for medical imaging, has published its consolidated and audited annual results for 2016.
March 29, 2017
Plasticell makes deal with two Singapore research centers
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
March 29, 2017
Port Erin Biopharma reports €0.5M profit for second half of 2016
Port Erin Biopharma Investments Limited has reported financial results for the six-month period ending 31 December 2016.
March 28, 2017
The Parker Institute for Cancer Immunotherapy, BMS, CRI join to fight cancer
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) have entered into a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks.